IDEAYA reports top line data from Phase II/III trial of darovasertib combo

IDEAYA Biosciences and Servier have reported positive top line results from the Phase II/III registration trial, OptimUM-02, ...
Hosted on MSN

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...
Hosted on MSN

AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial

AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet the primary endpoint in a Phase III trial. In the LATIFY trial (NCT05450692), ...
Benzinga.com

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial

Pfizer Inc. (NYSE: PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regimen demonstrated a statistically ...